Novel Magnesium Oxide (MgO) nanoparticles (NPs) modified with the polymer poliethylene glycol (PEG) were synthesized as carrier for the anticancer drug 2-Methoxyestradiol (2ME) to improve its clinical application. The functionalized NPs were characterized by Infrared spectroscopy with Fourier transform to elucidate the vibration modes of this conjugate, indicating the formation of the MgO-PEG-2ME nanocomposite. The studies of absorption and liberation determined that MgO-PEG-2ME NPs incorporated 98.51 % of 2ME while liberation of 2ME was constant during 7 days at pH 2, 5 and 7.35. Finally, the MgO-PEG-2ME NPs decreased the viability of the prostate cancer cell line LNCap suggesting that this nanocomposite is suitable as a drug delivery system for anticancer prostate therapy.
Introduction

1
Cancer is one of the diseases with higher prevalence in the population, being the second 2 cause of death in 2015, with a total of 8.8 million globally. It is expected that due to 3 the growth and aging of the population in the next two decades 22 million of people will 4 be diagnosed annually with this pathology [1, 2] . At global level the most common kinds 5 of cancer are; lung, breast, duodenum and prostate [2, 3] . Prostate cancer is the most 6 common type of carcinoma in male from developed and developing countries [4] . The 7 current therapies for prostate cancer are focused in surgery, radiation and hormonal 8 treatment. Unfortunately, survival prognostic for patients is very poor because many 9 patients will suffer from recurrence and subsequent metastasis [4] [5] [6] . Therefore, it is 10 necessary development new drugs and therapies that will be effective for the treatment 11 of prostate cancer. 2-Metoxyestradiol (2ME) has antitumor activity in several types of cancer of the 13 reproductive tract as prostate, cervix, ovary or endometrium. 2ME exerts its anticancer 14 activity via anti-proliferative, apoptotic or antiangiogenic effects on tumor cells [7] . 15 Despite to be considerate as a promising anticancer drug it has an unfavorable kinetic 16 with a low solubility in water; Thus, it is necessary to find new ways to facilitate its 17 administration to the human body. In this context, the nanoparticles (NPs) as drug 18 carriers can play a fundamental role to improvement biological parameters. Actually, it 19 has been proposed that polymeric NPs [8] or TiO 2 NPs coated with polyethylene glycol 20 (PEG) could be useful tools to load 2ME [9] . In the searching for new NPs suitable for 21 medical use, MgO NPs are also an excellent candidate because they are bio-friendly [10] . 22 It has been shown that MgO NPs are not toxic for a variety of human cell lines at 23 concentrations under 300 µg/ml [10] . MgO NPs has been also used as a carrier for the 24 antincancer drug doxorubicin indicating its utility for a controlled system of drugs 25 delivery [11, 12] . In this work, we first performed the physicochemical characterization
26
of MgO NPs coated with PEG and loaded with 2ME (MgO-PEG-2ME). The efficiency 27 of absortion and liberation of 2ME was then analyzed. Finally, the effect of
28
MgO-PEG-2ME NPs on the prostate cell line LnCap was assessed.
29
Materials and Methods
30
Synthesis MgO nanoparticles formed, it was dried and before calcined at 600
• C for 6 hours to give MgO [14] .
38
MgO nanoparticles functionalized with PEG and 2ME loading.
39
MgO NPs were covered with poliethylene glycol 600 (PEG600; Sigma Aldrich) using the 40 agitation method. For this, 50 mg of MgO NPs were dispersed on 50 ml MiliQ water 41 and stirred for 1 hour, then 88 µl of PEG 2mg/ml was added and stirred by 2 hours and 42 centrifuged for 30 minutes at 4500 g. temperature by using a Thermo Nicolet IS10 spectrometer provided with single bounce 58 Ge crystal Smart-iTR accessory.
59
Zeta potential
60
The zeta potential of the NPs were analyzed by dynamic light scattering in the Zetasizer 61 Nano ZS DST1070 cell (Malvern Instruments, UK) [15] . Preparations were dissolved in 62 1 ml phosphate buffered saline at pH 7.35. The Samples were evaluated in triplicate.
63
Ultra-high performance liquid chromatography (UPLC)
64
UPLC was performed using an Acquity system (Waters, Milford, MA, USA) equipped 65 with a binary solvent delivery pump, an autosampler and a tunable UV detector.
66
Chromatographic separation was performed using a Waters Acquity BEH C18 column water at a flow rate of 0.4 ml/min. Detection was performed at a wavelength of 290 nm 69 using a 10 µl injection volume; the mobile phase of water and methanol was maintained 70 at 27
• C. The internal chromatographic standard solutions (1, 5, 10, 50 and 100 mg/ml) 71 were freshly prepared in a volumetric flask along with the mobile phase [16] .
72
Efficiency of absorption and liberation
73
The 2ME entrapment efficiency was analyzed using an extraction method described in 74 our previously word [9] . 1 mg of MgO-PEG-2ME NPs was dispersed in 1 ml PBS, and 75 agitation on an orbital shaker at 100 rpm. Samples were taken at 5 min, 30 min, 1 h, 3 76 and 6 hours at 37
• C. The 2ME concentration was determined by UPLC using a 77 calibration curve. To measure 2ME release, 1 mg of MgO-PEG-2ME NPs underwent sequential bag dialysis at 37
• C with gentle shaking in 15 ml of PBS (pH 2, 5 and 7.35). 80 At each sampling time, 1 ml of the supernatant was removed and replaced with an 81 equivalent volume of PBS. The supernatants were analyzed by UPLC to determine 2ME 82 release.
83
Cell Culture
84
LNCap cells were grown in DMEM medium (Hyclone, USA) supplemented with sodium 85 pyruvate 1 mM, 10% heat-inactivated fetal bovine serum, 100 UI/ml penicillin, 100 86 µg/ml streptomycin under 5% CO 2 in 95% of air in a cell culture incubator at 37
• C.
87
The cells were used when reach to 70-80 % of confluency. For all experiments, 2.5×10
cells/well were seeded.
89
Treatments and Measurement of cell viability
90
LNCaP cells were treated with nanoparticles of MgO, MgO-PEG or MgO-PEG-2ME at 91 a concentration equivalent to 5 µM of 2ME. The cell viability was assessed by the Furthermore, as control we used a solution of 2ME 5 µM. Ethanol 0.01 % was used as 101 vehicle of the nanoparticles and 2ME. MgO-PEG-2ME respectively. The histogram distribution for pure MgO-NPs,
115
MgO-PEG and MgO-PEG-2ME is shown in the MgO-PEG-2ME are bigger than other nanoparticles.
119
The size of the NPs is an important parameter that determines his biocompatibility; 120 our results for TEM analysis show a wide size distribution, which could be optimal for 121 the internalization into the intracellular space via different mechanisms as endocytosis, 122 phagocytosis and pinocytosis. Particularly, endocytosis mediated by clathrin and 123 caveolae induce a greater accumulation of NPs inside the cells [17] . In addition, it must 124 be considered that for each NPs that is able to be transported across the cell membrane 125 exist an ideal radius that allows a rapid internalization. As this radius is approximately 126 90 nm for spherical conjugate NPs, we can assume that our NPs are suitable for cell 127 internalization [18] . Other variables that determine the biocompatibility of the NPs is 128 the superficial charge due to chemistry modification. The results of the zeta potential 129 measurements for MgO, MgO-PEG and MgO-PEG-2ME NPs are shown in the table 1. 130 We can observe a negative zeta potential increasing from -30 meV to -28.3 and -22.0 131 when PEG and 2ME are added suggesting that these NPs could be useful for biological 132 applications. In this context, It has been shown that NPs with positive zeta potential 133 could be more deleterious because induce platelet aggregation that can cause 134 thrombosis or they can interact with membrane phospholipid or proteins disrupting 135 stability of the cell surface [18] . Table 1 . Mean ± Zeta Potential.
136
NPs
Zeta Potential (mV) MgO -30.7 ± 0.6 MgO-PEG -28.3 ± 3.5 MgO-PEG-2ME -22.0 ± 10.8
Mean ± Zeta Potential for Nanoparticles of MgO, MgO-PEG and MgO-PEG-2ME NPs. MgO-PEG-2ME NPs.
138
To characterize and determine functional groups and modifications, FTIR 139 spectroscopy was performed on pure MgO-NPs, PEG and 2ME as well as in MgO-PEG, 140 MgO-PEG-2ME NPs and PEG-2ME. Fig 3A shows 2ME, that have been described previously by our research group [9] .
154
In the FTIR spectrum of MgO-PEG-2ME NPs, we found several changes including 155 new bands at 2861 cm −1 and 2919 cm −1 belonging the C-H stretching vibration in CH, 156 -CH 2 , -CH 3 . The band at 3382 cm −1 is related with the stretching vibration of hydroxyl 157 group, this band is broadened with an increased intensity with respect to pure 2ME.
158
The band localized between 1500-1460 cm −1 are attributed to bending modes of CH, corresponding to the methoxy group O-CH 3 and hydroxyl group C-OH from 2ME.
163
Finally, in the low frequency vibration of 1179-638 cm −1 several bands are overlapping 164 between 2ME and MgO-PEG which generate broader bands compared with MgO-PEG 165 NPs. The appearance of the characteristics bands of 2ME slightly shifted when 2ME is 166 conjugated with MgO-PEG (see Fig 3B in the range 1600-800 cm −1 ). This suggests 167 that the interaction of 2ME and PEG may occur through hydrogen bondings of the 168 hydroxyl groups present on the MgO-PEG surface. Furthermore, it is known that PEG 169 is not a purely hydrophilic polymer, being able to attach hydrophobic drug as 170 2ME [23, 24] . For corroborate this, we perform the spectra of PEG conjugated with 171 2ME without MgO-NPs, this is shown in the Fig 3C. In this figure we can observe that 172 the PEG-2ME bands are modified with respect to PEG and 2ME alone; the most 173 striking feature of PEG-2ME spectra is that, the bands became wider than PEG bands, 174 this may be originated from the association between OH group of PEG and hidroxyl 175 group of 2ME by hydrogen bonding. All these characteristic and those exposed above 176 indicate the attachment of 2ME to MgO-PEG NPs. A scheme of functionalized MgO
177
Nps with PEG and 2ME is shown in the 180 2ME and MgO-PEG-2ME NPs spectra in the range of [1800-600 cm −1 ]. In this zone we 181 can distinguish the principal functional groups of 2ME and the new bands that appear 182 in MgO-PEG when is conjugate with 2ME, where the mains bands are labeled. (C)
183
PEG, 2ME and PEG-2ME; this figure shows the modified band of PEG when is 184 conjugate with 2ME, where the mains bands are labeled. 
191
Kinetic of absorption and liberation.
192
To evaluate the 2ME-loading capacity of the MgO-PEG NPs, we performed an 193 extraction method in which an amount (i.e., 1 mg) of particles was dispersed in water to 194 release the encapsulated drug, and this solution was evaporated and subsequently 195 suspended in methanol for quantification by UPLC. The maximum absorption was 196 reached at 3 hours of incubation with a value of 0.985 ± 0.0011 mg/ml of 2ME 197 absorbed by each 1 mg/ml of MgO-PEG NPs that correspond to 98.51 % of absorption 198 of total weight; this amount keep stable until 6 hours of evaluation (see Fig 5) .
199
Fig 5. Absorption profile of 2ME by MgO-PEG NPs.
200
As the retention of the chemotherapeutic drug within the nanoparticle is 201 fundamental for its future clinical application, we then measured the liberation of 2ME 202 from the MgO-PEG NPs in non-biological conditions. As shown in Fig 6, we can 203 observe that 2ME is gradually released over a period of 168 hours (7 days at pH 2, 5 204 and 7.35). This shows that the drug is released in a sustained manner. The mean value 205 of release is about 33.9 %, 28.39 % and 30.16 % at pH 2, 5 and 7.35, respectively. The 206 maximum amount released is 2.95 µM that correspond to 89.27 % of the total of 2ME 207 loaded into MgO-PEG NPs, which is reached for a pH 5 at 96 hous. For a pH 7.35, the 208 maximum drug released was 44 % at 72 hours. These results suggest a high specificity 209 for any potential future use of this nanoparticle since less than 1% of 2ME would be 210 released into the circulation, and given the leaky blood vasculature that irrigates cancer 211 cells the MgO-PEG-2ME composite should be taken up preferentially. MgO-PEG NPs. ** P < 0.01, *** P < 0.001 214 Cell Toxicity.
215
Viability of LnCap cells treated with MgO NPs, MgO-PEG NPs, MgO-PEG-2ME NPs 216 at a concentration equivalent to 5 µM of 2ME were determined using an in vitro 217 viability assays (MTS). As shown in Fig 7, 2ME alone or loaded to MgO-PEG NPs 218 induce a significant decrease in cell viability around 40% at 72 hours. These results
219
indicate that 2ME absorbed with the MgO-PEG NPs maintains its anticancer 220 properties suggesting that this conjugate is a promising option for therapeutic use.
221
Interestingly, we also observed that pure MgO-NPs produce a significant decrease in the 222 cell viability to 20% at 72 hrs, which decreases when it is coated with PEG suggesting 223 that functionalization of MgO NPs with PEG reduces its intrinsic toxicity. This is may 224 be explained by the fact that PEG inhibit protein absorption and/or reduce surface 225 availability of NPs affecting their toxic activity [17, 21, 25] . nanoparticles of MgO, MgO-PEG, or MgO-PEG-2ME compared with 2ME 5 µM alone. 228 Ethanol 0.01% was used as Vehicle of the nanoparticles and 2ME. As positive control of 229
March 15, 2019 6/9 cytotoxicity we added hydrogen peroxide (H 2 O 2 ) 0.08 % dissolved in 4 µL of culture 230 medium. *P < 0.05, ** P < 0.01, *** P < 0.001.
231
Conclusion
232
Nanoparticles of MgO, MgO-PEG and MgO-PEG-2ME were characterized by TEM, 233 zeta potential and FTIR spectroscopy. The modification processes attributed to the 234 conjugation of PEG and 2ME into MgO NPs was performed step by step, where is 235 confirmed that 2ME is attached to funtionalized MgO-PEG NPs. The 2ME absorption 236 profile shows that a 98.51% of total weight is absorbed by MgO-PEG NPs. 2ME is 237 released from MgO-PEG NPs constantly over a period time reaching a maximum of 238 2.95 µM at 96 hrs corresponding to 89.27 % of the 2ME total loaded into MgO-PEG
239
NPs. In vitro viability assays (MTS) with the human prostatic adenocarcinoma cell line 240 LNCap showed that MgO-PEG-2ME NPs has anticancer activity as similar as 2ME
241
alone. In summary, we have developed a nanocarrier system based in MgO-PEG NPs 242 that can load and deliver 2ME into cancer cells suggesting to this 2ME loading strategy 243 as a promising option for use in malignant disease.The next steps of this investigation 244 will be focused to evaluate the anticancer activity of the MgO-PEG-2ME NPs on animal 245 models in order to assure its clinical applicability.
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